Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The rising case of rheumatoid arthritis drives the growth of the global HUMIRA (adalimumab drug) market. The number of rheumatoid arthritis disease cases was 35 million in 2021. The overall market is likely to grow at a CAGR of 1% in the forecast period of 2023-2031. With this growth rate, the number of cases is likely to reach nearly 38.3 million by 2030.
Adalimumab is a monoclonal antibody and disease-modifying anti-rheumatic drug that works by inactivating tumour necrosis factor alpha.
HUMIRA and Exemptia are two of its brand names. The original brand name of adalimumab drug is HUMIRA. The adalimumab biosimilar is the latest version of adalimumab. The biosimilar form of a biological medicine is the same as the original form. It is used to treat conditions such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and suppurative rhinitis.
The growth of HUMIRA (adalimumab drug) market is influenced by several factors, including the prevalence of arthritis and skin diseases, sedentary lifestyles, and the growing obesity population.
According to the research report, the market can be categorised into the following segments:
United States of America
United Arab Emirates
The rapidly growing cases of arthritis are propelling the demand for HUMIRA (adalimumab drug) market. This is largely a result of the increasing number of elderly people. Women are more likely to develop arthritis as they age since their bodies lose calcium.
The development of arthritis and psoriasis is linked to sedentary lifestyles. The drug is majorly consumed based on both of these factors. The HUMIRA (adalimumab drug) market is expected to grow further due to improvements in disease diagnostics and strong support for effective biopharmaceuticals.
HUMIRA (adalimumab drug) is an expensive drug due to its biological properties. A factor limiting the growth of the HUMIRA (adalimumab drug) market is the price of the therapy, which can be upto USD 5,000 per month. It remains a challenge for the market to handle the high cost of treatment procedures.
Furthermore, the arrival of new technologies and various therapeutic procedures aimed at benefiting end-users is likely to stimulate the global HUMIRA (adalimumab drug) market.
Increasing government investments are increasing the growth prospects of the global HUMIRA (adalimumab drug) market. The blockbuster drug's patent expiration has also provided new opportunities for major market players due to the entry of HUMIRA (adalimumab drug) into the market.
Also, HUMIRA (adalimumab drug) market growth will be slowed in part by the lack of qualified specialists to treat this disease with the right preparations.
Geographically, North America is the biggest market for innovative medicines that feature the newest technological advancements. The global HUMIRA (adalimumab drug) market growth rate is also being driven by factors such as availability of advanced medical equipment, technological advancements, and launches of many innovative drugs.
The fastest-growing market during the forecast period will be Asia Pacific due to increasing popularity and rising healthcare expenditure. A favourable regulatory policy for biosimilars is expected to boost the demand for HUMIRA (adalimumab drug) over the forecast period.
It is possible to use HUMIRA drugs as therapeutic platforms to treat a wide range of conditions. HUMIRA drugs have clinical applications in the treatment of various diseases.
HUMIRA (Adalimumab) is a monoclonal antibody designed to inhibit the effects of human tumor necrosis factor. HUMIRA contains heavy and light chains of human IgG1k with variable and constant regions.
A recombinant DNA technology is used to produce adalimumab in Chinese hamster ovary cells. Injections are prepared from it. This antibody binds specifically to TNF-α and blocks its interaction with the cell surface TNF receptors p55 and p75.
TNF is a naturally occurring cytokine that plays a role in the immune and inflammatory response of the body. One of the most important cytokines is tumor necrosis factor alpha. It plays an important role in the inflammatory chain reaction.
TNF modulates biological responses such as changes in adhesion molecules related to leukocyte migration when adalimumab is administered. Adalimumab is effective against autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis vulgaris due to its anti-TNF effects.
A number of diseases relating to the musculoskeletal system are associated with HUMIRA, such as arthritis, psoriasis, and arthritic conditions. HUMIRA drugs have therapeutic potential to control many diseases.
Numerous studies are being conducted to determine how HUMIRA can be used to treat and diagnose a variety of diseases. Various new drugs have appeared on the market, such as:
All these emerging drugs will drive the global HUMIRA (Adalimumab drug) market.
The report gives an in-depth analysis of the key players involved in the global HUMIRA (Adalimumab drug) market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Indication||
|Breakup by Type||
|Breakup by Dosage Strength||
|Breakup by Drug Type||
|Breakup by Route of Administration||
|Breakup by Distribution Channels||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Humira (Adalimumab) Drug Overview
4.1 Drug Overview
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Humira (Adalimumab Drug) Market
6.1 Global Humira (Adalimumab Drug) Market Overview
6.2 Global Humira (Adalimumab Drug) Market Analysis
6.2.1 Market Overview
220.127.116.11 Global Humira (Adalimumab Drug) Market Historical Value (2016-2022)
18.104.22.168 Global Humira (Adalimumab Drug) Market Forecast Value (2023-2031)
6.3 Global Humira (Adalimumab Drug) Market by Indication
6.3.1 Market Overview
22.214.171.124 Rheumatoid Arthritis
126.96.36.199 Ankylosing Spondylitis
188.8.131.52 Chronic Plaque Psoriasis
184.108.40.206 Crohn’s Disease
220.127.116.11 Ulcerative Colitis
18.104.22.168 Psoriatic Arthritis
6.4 Global Humira (Adalimumab Drug) Market by Type
6.4.1 Market Overview
6.5 Global Humira (Adalimumab Drug) Market by Dosage Strength
6.5.1 Market Overview
6.6 Global Humira (Adalimumab Drug) Market by Drug Type
6.6.1 Market Overview
6.7 Global Humira (Adalimumab Drug) Market by Route of Administration
6.7.1 Market Overview
6.8 Global Humira (Adalimumab Drug) Market by Distribution Channels
6.8.1 Market Overview
22.214.171.124 Hospital Based Pharmacies
126.96.36.199 Online Pharmacies
188.8.131.52 Retail Pharmacies
6.9 Global Humira (Adalimumab Drug) Market by Region
6.9.1 Market Overview
184.108.40.206 North America
220.127.116.11 Asia Pacific
18.104.22.168 Latin America
22.214.171.124 Middle East and Africa
6.9.2 North America
126.96.36.199 Historical Trend (2016-2022)
188.8.131.52 Forecast Trend (2023-2031)
184.108.40.206 Break Up by Country
220.127.116.11.1 United States of America
18.104.22.168 Historical Trend (2016-2022)
22.214.171.124 Forecast Trend (2023-2031)
126.96.36.199 Break Up by Country
188.8.131.52.1 United Kingdom
6.9.4 Asia Pacific
184.108.40.206 Historical Trend (2016-2022)
220.127.116.11 Forecast Trend (2023-2031)
18.104.22.168 Break Up by Country
6.9.5 Latin America
22.214.171.124 Historical Trend (2016-2022)
126.96.36.199 Forecast Trend (2023-2031)
188.8.131.52 Break Up by Country
6.9.6 Middle East and Africa
184.108.40.206 Historical Trend (2016-2022)
220.127.116.11 Forecast Trend (2023-2031)
18.104.22.168 Break Up by Country
22.214.171.124.1 Saudi Arabia
126.96.36.199.2 United Arab Emirates
188.8.131.52.4 South Africa
7 Current Scenario Evaluation and Regulatory Framework
7.1 Emerging Therapies and Clinical Trials Synopsis
7.2 Patent Landscape
7.2.1 Patent Overview
184.108.40.206 Patent Status and Expiry
220.127.116.11 Timelines from Drug Development to Commercial Launch
18.104.22.168 New Drug Application
22.214.171.124.1 Documentation and Approval Process
7.3 Cost of Treatment
7.4 Investment Scenarios
7.5 Regulatory Framework
7.5.1 Regulatory Overview
126.96.36.199 US FDA
188.8.131.52 EU EMA
184.108.40.206 INDIA CDSCO
220.127.116.11 JAPAN PMDA
8 Challenges and Unmet Need
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Rate
8.3 Awareness and Prevention Gaps
9 Global Humira (Adalimumab Drug) Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Drug Adoption Parameters
9.4 Porter’s Five Forces Model
9.5 Key Demand Indicators
9.6 Key Price Indicators
9.7 Value Chain Analysis
10 Supplier Landscape
10.1 AbbVie Inc.
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.2 Amgen Inc.
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.3 Fresenius Kabi AG
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.4 Celltrion Healthcare Co Ltd
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.5 Alvotech Ehf.
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.6 Bio-Thera Solutions Ltd.
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.7 Zydus Lifesciences Limited
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.8 Hetero Healthcare Ltd.
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.9 Innovent Biologics, Inc.
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.10 Novartis International AG (Sandoz)
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.11 Reliance Life Sciences Pvt. Ltd.
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.12 Samsung C&T Corporation
10.12.1 Company Overview
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.13 Terumo Corp.
10.13.1 Company Overview
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.14 Torrent Pharmaceuticals Ltd.
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
11 Recommendations and Discussion
12 Pricing Models and Strategies (Additional Insight)
12.1 Cost Model
12.1.1 Manufacturing Cost Analysis
12.1.2 Procurement Cost Analysis
12.2 Pricing Strategies
12.2.1 Competitor Pricing Analysis
12.2.2 Key Assessment of Product Attributes
12.2.3 Pricing Benchmark
13 Global Humira (Adalimumab) Drug Distribution Model (Additional Insight)
13.2 Potential Distributors
13.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
The prevalence rate of global HUMIRA (Adalimumab drug) market is likely to grow at a CAGR of 1% during the forecast period of 2023-2031.
Asia Pacific region has the highest growth rate in the HUMIRA (Adalimumab drug) market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market.
North America dominated the HUMIRA (Adalimumab drug) market and is expected to grow during the forecast period due to excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.
AbbVie Inc., Amgen Inc., Fresenius Kabi AG, Celltrion Healthcare Co Ltd, Alvotech Ehf., Bio-Thera Solutions Ltd., Cadila Healthcare Ltd., Hetero Healthcare Ltd., Innovent Biologics, Inc., Novartis International AG are the key companies in the global HUMIRA (Adalimumab drug) market.
The factors stimulating the development of the market include increased government initiatives, optimal costs, and a rise in R&D expenditure in biopharmaceutical companies.
The high cost of clinical trials and research and development represents a major challenge for market participants. Despite heavy R&D spending, manufacturers must keep their products low, which limits growth opportunities in the HUMIRA market.
IBI303 and CT-P17 are the emerging drugs that will appear in the market
HUMIRA is a medicine used to treat ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ulcerative colitis, hidradenitis suppurativa and other diseases affecting the musculoskeletal system.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.